S. 1637 · 119th Congress · Health
MVP Act
- IntroducedMay 7, 2025 Done
- CommitteeReferred to Finance Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)
The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.
Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.
Congressional Research Service · summary of “Introduced in Senate” version · May 7, 2025
Who lobbies on it
8 organizations, more than 95% of Senate bills · 27 filings, incl. 1 naming only H.R. 7871 · Q2 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named S. 1637 or H.R. 7871 that quarter.
-
America's Health Insurance Plans Inc (ahip)
6 of 6 quarters
“…H.R. 7871 - MVP Act - Rep. Guthrie, Brett - Value-based purchasing arrangements in Medicaid H.R. 8375 - Medicare Advantage Improvement Act - Rep. Joyce, John - MA programmatic reforms H.R. 8377 - Stop Deadly Denials Act - Rep. Khanna, Ro - MA prior authorization prohibition H.R. 8875 - Improving Home Dialysis Act…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both
-
Alliance for Regenerative Medicine
4 of 6 quarters
“…MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.”
$360K lobbying spend in 2026 to date, all issuesQ1 2026 filing
-
Pharmaceutical Care Management Association
3 of 6 quarters
“S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800…”
$9.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both
5 more organizations, every filingPROUpgrade
Organizations that named S. 1637 or its companion H.R. 7871 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Reports naming only H.R. 7871 are included and tagged. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Members sponsoring the companion, H.R. 7871, are counted on that bill’s page, not here. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- May 7, 2025Read twice and referred to the Committee on Finance.
- May 7, 2025Introduced in Senate